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Purpose: To evaluate the effects of angiotensin-converting enzyme inhibitors (ACE-I) in retarding 
progression of severe non-proliferative diabetic retinopathy (NPDR) in normotensive type 2 diabetic patients. 
Methods: This was a retrospective case control study of 128 patients with normotensive type 2 diabetes 
with lower than +1 dipstick proteinuria and severe NPDR who were classified into either an ACE-I treated 
group (Enalapril maleate 10 mg, n=12 , Ramipril 5 mg, n=17) or an ACE-I untreated group (n=99). Medical 
records were reviewed for endpoints of (a) occurrence of proliferative diabetic retinopathy (PDR) or macular 
edema (ME) for which laser phototherapy was necessary or (b) development of proteinuria of higher than 
+1 level requiring medication of ACE-I.
Results:  From the total of 128 patients, there were 29 ACE-I treated patients and 99 ACE-I untreated 
patients. There were no differences in the average age, duration of diabetes, body mass indices, blood 
pressure and levels of hyperglycemia or HbA1C between the two groups. Blood pressure and HbA1C levels 
in both groups remained unchanged during the study. The mean follow-up period was 41.6 months. In the 
ACE-I group, 6 patients progressed to PDR, 5 to ME and 6 developed proteinuria of greater than +1 over 
the follow-up period. In the control group, 30 patients progressed to PDR, 6 to ME and 9 developed 
proteinuria of greater than +1 over the follow-up period.
Conclusions: Small doses of ACE-I did not yield any beneficial effects in retarding the progression of 
severe NPDR.
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Diabetic retinopathy is one of the main causes of vision 
loss, even in developed countries.
1 Even though the etiology 
of diabetic retinopathy has yet to completely defined, it is 
widely accepted that the control of risk factors, such as blood 
sugar and blood pressure level, retards the progress of this 
disease.
2,3 Although laser photocoagulation is recognized as 
a definitive method for slowing down the aggravation of 
severe non-proliferative diabetic retinopathy (NPDR) and 
proliferative diabetic retinopathy (PDR), it is accompanied by 
complications including pain, reduced vision, narrowed visual 
field, macular edema, macular coagulation, choroidal 
detachment, exudative retinal detachment and vitreous 
hemorrhage, and in rare cases, damage to other structures in 
the eye.
4 Therefore, clinical studies are underway to find 
non-invasive methods for the treatment of diabetic retinopathy. 
Recently, the rennin-angiotensin system (RAS) was found to 
interfere with the development of PDR,
5 consistent with all 
the RAS components being found in the retina, and the 
densities of prorenin, renin, angiotensine II increasing in the 
vitreous of patients with PDR and macular edema (ME).
5-10 
Further, patients with diabetic retinopathy had higher 
levels of angiotensin-converting enzyme (ACE),
11 and the 
angiotensine II formed by ACE promotes the expression of 
growth factors, such as vascular endothelial growth factor 
(VEGF), insulin-like growth factor (IGF) and platelet-derived 
growth factor (PDGF), which in turn result in formation of 
new blood vessels and increased permeability of blood 
vessels and oxidative stress.
5,7,12,13 As a result, angiotensin- 
converting enzyme inhibitor (ACE-I) can prevent destruction 
of blood retina barrier (BRB)
5,12 and retard progression of the 
disease to PDR.
14
A few reports addressed the effects of ACE-I on the patients 
with diabetic retinopathy but the authors differed in their 
interpretation of the data. Consequently, our clinical research 
sought to clarify preventive effects of ACE-I on the aggravation 
process from NPDR to PDR in patients with type 2 diabetes.
Materials and Methods
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diabetes at our hospital from January 1998 to December 
2002, we performed retrospective reviews on 240 of them 
who had been under continuous observation for over 10 years 
by the Departments of Ophthalmology and Endocrinology & 
Metabolism with visits every six months until December 
2004. A diagnosis of type 2 diabetes was determined by 
personal medical history, positive test results, physical 
examination, and clinical manifestations in at least two 
follow-up visits. Among these type-2 diabetics, we excluded 
patients who maintained normal blood pressure of under 
140/90 mmHg without anti-hypertensive drugs and selected 
the ones diagnosed with severe NPDR confirmed by two 
successive examinations of the fundus at least 6 months 
apart. We selected 128 patients with normal blood creatinine 
levels, who tested negative or less than +1 in dipstick test 
for proteinuria, and with a maximum corrected vision of 
greater than 20/50. We also eliminated patients with a past 
history of general diseases other than diabetes or ones who 
received eye surgery other than for cataracts. After sorting 
our final test subjects into one of two groups, one group 
medicated with ACE-I (the Test Group) and the other without 
ACE-I treatment (the Control Group), we compared the 
fundus examination results and clinical data between the two 
groups. The ACE-I drugs used were of 2 types: Enalapril 
maleate 10 mg (Renatone
Ⓡ), and Ramipril 5 mg (Tritrace
Ⓡ).
Examination of the fundus was performed with a 78D 
(Volk lens, superfield) lens, slit lamp microscope and indirect 
ophthalmoscope following pupillary dilatation with 
phenylephrine HCL 2.5% (Mydfrin) and tropicamide 1% 
(Mydriacyl) administered 3 times, 15 minutes apart. Through 
examination of the fundus, diabetic retinopathy was classified 
as mild, moderate or severe phases, in accordance with the 
40-50 levels in the modified Arlie House classification,
15 and 
confirmed by fluorescein fundus angiography (FAG). We 
checked blood creatinine, HbA1C and proteinuria levels and 
their maximum corrected vision. During the follow up period, 
photographs of the fundus were taken once every year 
regardless of the slit lamp microscopy results. If severe 
diabetic retinopathy with a 60-80 level by modified Airlie 
House classification or macula edema was observed through 
slit lamp microscopy, the FAG was performed again to 
confirm the diagnosis.
15 The terminating criteria for patients 
in this study were defined as aggravation of severe NPDR 
into PDR requiring laser photo-coagulation treatment, 
occurrence of macula edema, observed through fundus 
examination and FAG, or positive results of a proteinuria test 
with levels higher than +1 requiring medication by ACE-I.
SPSS 11.0 was used for statistical analysis, while Student's 
t-test and Chi-square methods were used for comparison of 
earlier data and termination points between the Test Group 
and the Comparison Group. The paired t-test was used for 
the comparison of the changes in the primary and the final 
mean arterial pressure in the two groups. The results of these 
statistical tests were considered meaningful only when the 
p-value was less than 0.05.
Results
The average age of the 128 patients was 61.7±3.9 (range, 
51 to 78 years), and the patients consisted of 63 men and 
65 women. The group medicated with ACE-I (Group 1) was 
composed of 29 patients, and the Control Group (Group 2) 
had 99 patients. For the two ACE-I drugs, 10 mg of Enalapril 
maleate 10 mg (Renatone
Ⓡ) was administered to 12 patients, 
while 5 mg of Ramipril 5 mg (Tritrace
Ⓡ) was given to 17 
patients.
The average age of Group 1 was 59.1±2.5, with 11 men 
(37.9%) who had diabetes for an average of 15.5±2.7 years. 
Among the patients of Group 1, 9 were treated with oral 
medications (pills), 10 were treated with insulin, and 10 were 
treated with oral medication and insulin. The blood creatinine 
levels were 0.78±0.08 mmHg, and HbA1c levels were 10.4
±0.9%. The average age of Group 2 was 62.5±4.0, with 
52 men (52.5%) who had diabetes for an average of 16.4±
3.3 years. Among the patients of Group 2 , 38 were treated 
with oral medications (pills), 38 were treated with insulin, 
and 23 were treated with oral medications and insulin. The 
blood creatinine levels were 0.83±0.11 mmHg, and HbA1c 
levels were 10.0±1.2%. There were no significant 
differences between two groups in the male/female ratio, how 
long the patients had diabetes, or in blood pressure readings. 
Otherwise, the age (p=0.00) and serum creatinine levels 
(0.039) in Group 2 were higher than those in Group 1, and 
the body mass index (BMI) (p=0.005) and HbA1c (p=0.045) 
values of Group 1 were higher than those in Group 2 (Table 
1). In Group 1, 6 patients showed aggravation of severe 
NPDR into PDR, requiring laser photo-coagulation treatment, 
macula edema occurred in 5 patients, and 6 patients showed 
positive results of proteinuria, with levels greater than +1. In 
Group 2, 30 patients showed aggravation of severe NPDR 
into PDR requiring laser photo-coagulation treatment, macula 
edema occurred in 6 patients, and 9 patients showed positive 
results of proteinuria, with levels greater than +1. Taken 
together, 62 patients out of the original pool of 128 satisfied 
the terminating criteria of this study during the observation 
period of the average 41.6±16.3 months. The average 
observation period was 37.4±14.0 months in Group 1 and 
42.9±16.8 months in Group 2, with no significant difference 
between the two groups (P=0.115). In Group 1, severe NPDR 
was aggravated into PDR in 6 patients (20.7%), macular 
edema occurred in 5 patients (17.2%), and proteinuria values 
rose to over 1+ in 6 patients (20.7%). In Group 2, severe 
NPDR was aggravated into PDR in 30 patients (30.3%), ME 
occurred in 6 patients (6.1%), and proteinuria values rose to 
over 1+ in 9 patients (9.1%) (Table 2, Fig. 1).
In Group 1, the average arterial pressure was 94.7±7.5 
mmHg at the first examination, and 92.4±6.4 mmHg at the 
final examination (P=0.075). In Group 2, the average arterial 
pressure was 90.3±5.4 mmHg at the first examination, and 
90.3±5.4 mmHg at the final examination (P=0.98), with no 
significant differences between the two groups.Kor J Ophthalmol Vol.21, No.1, 2007
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  Group 1
‡ Group 2
§ P-value
Number of patients  29 99
Age (years) 59.1±2.5 62.5±4.0 P=0.00
Π
Gender (M/F) 11/18 52/47  P=0.121
#
Duration of diabetes (years) 15.5±2.7 16.4±3.3 P=0.192
Π
BMI
* (kg/m
2) 27.0±2.5 25.5±1.6 P=0.005
Π
MAP
†(mmHg) 94.7±7.5 90.3±5.4 P=0.088
Π
Serum creatinine (mg/dl)  0.78±0.08  0.83±0.11 P=0.039
Π
Pills only/insulin only/both 9/10/10 38/38/23 P=0.165
Π
Hb A1C (%) 10.4±0.9 10.0±1.2 P=0.045
Π
* BMI: Body mass index. 
†MAP: Mean arterial pressure. 
‡Group 1: ACE-I treated group. 
§ Group 2: Control group. 
Π Paired t-test (Group1 vs Group 2).
# Chi-square (Group1 vs Group 2).
Table 1. Baseline characteristics 
 
  No. of patients 
Duration (ms
*)  before 24 M  30 M 36 M 42 M after 48 M 
Group 1
PDR
† 2  1 1 0 2
ME
‡ 03  1  0 1  
≥ +1 Proteinuria 2  0 1  2  1 
Group 2
P D R 4 780 1 1
M E 0 0510
≥ +1 Proteinuria 1  3  0 3  2 
P-value
§  0.117 0.332 0.598 0.350 0.464
* Ms : months. 
†PDR : proliferative diabetic retinopathy. 
‡ME : macular edema. 
§ Chi-square (Group 1 vs Group 2).
Table 2. Patients reaching study endpoints 
Discussion
It is well established that early diagnosis and treatment of 
diabetes can reduce the chance of blindness caused by 
diabetes and that rigorous control of blood sugar and 
hypertension retards occurrence and progress of diabetic 
retinopathy.
16-18 Recently, it was found that controlling RAS 
affects the onset and progress of diabetic retinopathy.
5-10 
Chaturvedi et al
14 performed a compare and contrast study of 
EUCLID (EURODIAB Controlled Trial of Lisinopril in 
Insulin-Dependent Diabetes Mellitus) on type 1 diabetes and 
showed that administration of Lisinopril reduced progress of 
diabetic retinopathy by 50%, with an 80% reduction of 
aggravation into PDR in comparison with the placebo group 
(P<0.02) after two years.
8 These studies showed that HbA1c 
was 0.4% lower in the test group where the Lisinopril had 
been administered, but there were no significant differences 
between the two groups (P<0.06). These results suggest that 
well-controlled blood sugar in the group taking ACE-I before 
the study may have accounted for the improved results in 
diabetic retinopathy. As for effects on blood pressure, only 
a small decrease of 3 mmHg was observed after one month 
from the administration of Lisinopril
14 Jackson et al.
19 
published a clinical study on the therapeutic effect of ACE-I 
on diabetic retinopathy without the control group. Out of 10 
patients with 20 eyes with type 1 diabetes, 9 eyes exhibited 
aggravation; 4 eyes did not show any changes, and 7 eyes 
showed improvements in diabetic retinopathy over 2 years. YJ Cha, et al. THE THERAPEUTIC EFFECTS OF ACE-I'S IN SEVERE NPDR
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Group 1
*  ( N = 29 )
   PRO
§
6 (20.7%)
    ME
‡
 5 (17.2%)
  PDR
†
6 (20.7%)
Group 2
Π
( N = 99 )
   PDR
30(30.3%)
ME
6 (6.1%)
PRO
9 (9.1%)
Fig. 1. Patients reaching study endpoints.
* Group 1 : ACE-I treated group.
†PDR : proliferative diabetic retinopathy.
‡ME : macular edema.
§ PRO : ≥ 1+ Proteinuria.
Π Group 2 : Control group (ACE-I  untreated).
 Baseline Last p-value
‡
* Group 1 94.7±7.5 92.4±6.4 0.08
†Group 2 90.3±5.4 90.3±5.4 0.98
* Group 1: ACE-I treated group. 
†Group 2: Control group. 
‡Paired t-test. 
Table 3. Mean arterial pressure (mmHg±standard
deviation) values
These outcomes on the therapeutic effect of ACE-I are not 
sufficient to affirm whether the slowdown of progression of 
diabetic retinopathy was due to the decrease of blood 
pressure or to RAS. Therefore, the therapeutic effect of 
ACE-I on diabetic retinopathy patients with normal blood 
pressure was subsequently studied. Rachmani et al.
20 
observed 250 non-hypertensive type 2 diabetic patients who 
had not reported any problems with diabetic retinopathy. 
Among these 250 patients, a test group of 126 patients were 
given 10 mg of Enalapril on a daily basis, and the control 
group of 124 patients were given a placebo. These two 
groups of patients were tracked for 5 to 6 years, and diabetic 
retinopathy occurred to 9 patients (7.1%) in the test group, 
while 23 (18.5%) patients in the control group showed an 
11.5% reduction in absolute risk level.
While several reports have covered the retarding effect of 
ACE-I on the occurrence of diabetic retinopathy and 
aggravation of mild NPDR, there have been few reports on 
the therapeutic effect of ACE-I on severe NPDR related to 
aggravation into PDR. We showed that the there was no 
statistically meaningful effects of ACE-I in non-hypertensive 
(normotensive) type 2 diabetic patients for retarding the 
progression of severe NPDR into PDR over our average 
observation period of 41.6+16.3 months (Table 2). Eight out 
of 29 patients administered reached one of the pre-determined 
termination points of this clinical study within 36 months of 
administration. This result is similar to that reported by 
Pradhan et al.
21 who studied 35 type 2 diabetic patients with 
normal blood pressure. These 35 patients were classified into 
one of 2 groups at random, the test group of 18 patients who 
were given 5 mg of Enalapril and the control group of 17 
patients who were given a placebo (multivitamin) for an 
average observation period of 7.2 months. This study was 
discontinued, as no meaningful differences were found 
between the two groups.
In addition, we showed that PDR occurred to 6 medicated 
patients from Group 1 (20.7%) and 30 non-medicated patients 
from Group 2 (30.3%), supporting the partial retarding effect 
of ACE-I on the aggravation of the diabetic retinopathy to 
PDR. However, overall result of the experiment in terms of 
reaching the pre-determined termination point did not show 
significant differences between the two groups (Fig. 1). 
Among the 11 patients who acquired macular edema at the 
end of this study, none were compromised temporarily or 
permanently following cataract surgery.
Though this was a retrospective clinical study, we 
encountered the following limitations: It was difficult to 
match the patients in the two different groups by gender, age 
and other factors. The BMI and HbA1c in Group 1 were 
higher than those in Group 2 and the age and serum 
creatinine levels in Group 2 were higher than those in Group 
1. Although serum creatinine levels between the two groups 
were different, it was meaningless, because serum creatinine 
levels of all the subjects in this study were within normal 
range. The mean BMI values between two groups were 
different, but both values were in the overweight range, and 
so the mean BMI values were also such that they were also 
πKor J Ophthalmol Vol.21, No.1, 2007
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not meaningful in this study. Short-term fluctuations in blood 
sugar level were inevitable due to the long duration of 
diabetes. In addition, other variable factors (for example,. 
physical exercise, dietetic therapy, and effects on diabetic 
retinopathy affected by the improvement of renal and cardiac 
function after administration of ACE-I) were difficult to 
control. During the retrospective observation period, average 
HbA1c levels, which reflects control of blood sugar, 
remained as high as greater than 10%, suggesting that blood 
sugar had been out of control for a long period of time. This 
seems to be supporting the inevitability of fluctuation of 
short-term blood sugar levels and the difficulties in keeping 
the blood sugar level under control for the patients who have 
passed more than 10 years after being diagnosed with 
diabetes. Taking this fact into consideration, Orchard et al
22 
determined the relationship between cumulative glycemic 
exposure, which reflects both the level and duration of 
hyperglycemia, and micro-vascular complications. In this 
study, "A1 months", which is the result of multiplying 
HbA1c level higher than normal by time lag in months 
between the measurements, was used to reflect the level of 
excess glycosylated Hemoglobin in a certain time period. 
This method seems to be meaningful in the short period of 
most clinical studies.
It is possible that the small amount of ACE-I used in this 
clinical study may have failed to keep the RAS under control. 
However, the actual prescribed amount used in general 
practice has been recorded, and follow-up studies are 
warranted.
Even though we did not find the retarding or preventative 
effects of ACE-I on diabetic retinopathy in this study, 
long-term, massive and prospective clinical studies with 
stricter variants (for example, age, gender, serum creatinine 
level, HbA1c, BMI, and MAP) to prevent the statistical 
biases are still warranted in the future, as diabetes is a 
long-term disease.
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